Timing clarification: Healthpeak Properties is scheduled to release Q2 results after today’s close, Tuesday, August 4, 2026. The earnings call is tomorrow, Wednesday, August 5, at 10:00 a.m. ET. The August 4 event is the release, not the conference call.
The central question is no longer whether Healthpeak can stabilize its story. Q1 established credible momentum across outpatient medical, life science leasing, senior housing and capital allocation. The question now is whether operating results are improving quickly enough to justify the stock’s substantial rerating.
DOC closed August 3 at $21.65, up approximately 34% year to date and 31% since the May 5 Q1 release. At that price, it trades around 12.5x the midpoint of 2026 adjusted FFO guidance and yields approximately 5.6%.
That means a routine guidance reaffirmation with mixed operating details may not be enough. Investors will want evidence that:
Healthpeak’s current 2026 guidance is:
| Metric | Current guidance |
|---|---|
| Adjusted FFO/share | $1.71–$1.75 |
| Nareit FFO/share | $1.68–$1.72 |
| Total same-store adjusted NOI growth | -1% to +1% |
Q1 adjusted FFO was $0.45 per share. Management indicated that Q1 was somewhat elevated and described the remaining quarterly run rate as approximately $0.43, plus or minus $0.01.
Accordingly, a reasonable company-cadence benchmark for Q2 is approximately $0.42–$0.44 of adjusted FFO:
For a REIT, adjusted FFO, same-store NOI and occupancy are more informative than GAAP EPS, which can be distorted by depreciation and transaction gains.
Life science remains the largest source of both risk and upside.
In Q1:
The Q2 numbers may still be uneven. Management previously identified roughly 50,000 square feet of expected midyear tenant departures, while more than 500,000 square feet of scheduled commencements were expected to offset approximately 400,000 square feet of 2026 expirations.
Best-case outcome: Management raises or strengthens its occupancy outlook and shows that current leasing is producing visible 2027 NOI growth.
Warning sign: A shrinking pipeline, delayed commencements or sharply weaker economics despite optimistic demand commentary.
Outpatient medical is the dependable part of the portfolio. Q1 produced:
Investors should focus on whether Q2 maintains positive renewal spreads without materially higher tenant-improvement costs. Occupancy should also begin benefiting from the strong post-Q1 leasing pipeline.
A quarter with roughly 2%–3% same-store growth, positive spreads and continued low capital costs would reinforce the segment’s role as a reliable cash-flow compounder.
Also watch for additional outpatient joint ventures. Healthpeak said it was pursuing transactions capable of generating $700 million or more of proceeds, following the Blackstone recapitalization completed at a 6.1% cash cap rate. Closing these transactions near indicated pricing would support management’s argument that DOC’s private-market asset values exceed its public valuation.
Healthpeak owns approximately 81.6% of Janus Living, which reports after the close today as well. Janus will hold its call Wednesday at noon ET, two hours after DOC’s call.
Janus entered Q2 with:
The key questions are whether the $400 million acquisition package closed on schedule and whether operator transitions remained stable. Management did not expect a major occupancy benefit from the transitioned portfolio until the second half, potentially Q4, so Q2 should be judged primarily on execution and forward indicators.
At Janus’s August 3 closing price of $29.56, Healthpeak’s approximately 214.7 million-share/unit interest has a gross market value of roughly $6.35 billion, or about $9.20 per DOC share. That is not an incremental asset to simply add to DOC’s consolidated value, but it is an important source of valuation transparency—and Janus’s stock has risen approximately 25% from its first trading-day close.
The current adjusted FFO range leaves room for a modest raise if operating performance and transaction timing have been favorable. However, several offsets need to be considered:
The strongest report would combine an FFO beat with an improved full-year outlook, rather than merely benefiting from timing. Investors should therefore examine the bridge between operating outperformance, interest expense, asset sales and capital deployment.
| Outcome | What it would likely include |
|---|---|
| Bullish | Adjusted FFO of at least $0.44; guidance raised; lab occupancy and pipeline improve; Janus acquisitions close on schedule; additional recap proceeds become visible. |
| Neutral | Adjusted FFO of $0.42–$0.44; guidance reaffirmed; lab occupancy remains choppy but year-end target is maintained; outpatient and senior housing remain strong. |
| Bearish | Adjusted FFO below $0.42; lab pipeline fails to convert; occupancy target is softened; Janus acquisitions or capital recycling are delayed; refinancing costs pressure guidance. |
Lab occupancy is the key operating KPI, but guidance is likely to determine the stock reaction. Outpatient medical and senior housing already have strong narratives; the next leg of upside requires tangible evidence that lab leasing is moving from pipeline statistics into occupied, rent-paying space.
With DOC up more than 30% since Q1, expectations are materially higher. A simple “steady quarter” may preserve the thesis, but further appreciation likely requires some combination of a guidance increase, stronger lab visibility and successful capital recycling.